{"schema_version":"secwatch.filing_event.v1","accession":"0001689375-22-000010","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.663981+00:00","generated_at":"2026-06-24T00:55:29.384296+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Entrada Therapeutics reports Q2 2022 net loss of $23.2M; cash runway into 2H 2024","bullets":["Cash, cash equivalents and marketable securities $244.3M as of June 30, 2022, sufficient into 2H 2024.","Net loss $23.2M vs $9.9M in Q2 2021; R&D $16.2M (up from $6.8M), G&A $7.3M (up from $3.1M).","On track to file IND for ENTR-601-44 (Duchenne) in Q4 2022; ENTR-701 named as first DM1 clinical candidate.","Appointed Karla MacDonald as Chief Corporate Affairs Officer.","Entered collaboration with Myotonic Dystrophy Clinical Research Network for natural history study."],"urls":{"canonical":"https://secwatch.observer/filing/0001689375-22-000010","json":"https://secwatch.observer/filing/0001689375-22-000010.json","markdown":"https://secwatch.observer/filing/0001689375-22-000010.md","text":"https://secwatch.observer/filing/0001689375-22-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000010/0001689375-22-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000010/trda-20220811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:55:29.384296+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}